Navigation Links
Amicus Therapeutics Provides Positive Data Update from Phase 2 Long-Term Extension Study of Amigal™ for Fabry Disease
Date:2/16/2011

or the treatment of genetically defined sub-populations of patients with Parkinson's disease and Alzheimer's disease.  Amicus previously reported encouraging results from preclinical studies evaluating the use of a pharmacological chaperone for the treatment of Parkinson's disease.  Amicus will present additional data from preclinical studies that evaluated the pharmacological chaperone AT2101 in mouse models of Parkinson's disease as well as data related to the properties of new compounds, including AT3375.  In 2011, the Company expects to complete late-stage preclinical proof of concept studies, including IND-enabling activities, for AT3375.  The Amicus Parkinson's Disease program is funded in part by a grant from The Michael J. Fox Foundation (MJFF).

Additionally, Amicus continues to advance its preclinical program evaluating a pharmacological chaperone approach for the treatment of Alzheimer's disease.  The Company will present scientific data on the link between lysosomal dysfunction and neurodegeneration, including data related to a preclinical program evaluating a pharmacological chaperone approach for the treatment of Alzheimer's disease.   The Company expects to continue preclinical proof of concept studies during 2011.  The Amicus Alzheimer's Disease program is funded in part by a grant from the Alzheimer's Drug Discovery Foundation (ADDF).About AmigalOn October 29, 2010, Amicus announced a definitive agreement with GlaxoSmithKline PLC (GSK) to develop and commercialize Amigal (migalastat HCl), currently in Phase 3 for the treatment of Fabry disease as a monotherapy. Under the terms of the agreement, GSK received an exclusive worldwide license to develop, manufacture and commercialize migalastat HCl. GSK and Amicus are also investigating Amigal as a treatment for Fabry disease when co-administered with ERT and have commenced a Phase 2 study as noted above.  

The Phase 3 study (Study 011) of migalastat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
2. Amicus Therapeutics Opens Research Facility in San Diego
3. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
5. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
6. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
7. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
8. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
9. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
10. Amicus Therapeutics Announces Change to Board of Directors
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014   Global Science & Technology, ... products and services for satellite and weather systems, ... Integrated Services (OASIS) from the General Services Administration ... to provide the government best-value solutions for complex ... category in Pool 4. The OASIS SB award ...
(Date:9/15/2014)... Things can go downhill fast when a patient has ... multiply in a patient,s blood -- often too fast ... the human spleen and developed by a team at ... transform the way doctors treat sepsis. , "Even ... in intensive care units at least 30 percent of ...
(Date:9/15/2014)... , Sept. 15, 2014  iVinci Health LLC, ... comprehensive Patient Revenue Management system, branded as VisitPay®, has ... also announced the launch of a new extension to ... provides an easy and convenient way for patients to ... balances owed by them and their families. ...
(Date:9/15/2014)... 15 septembre 2014 La deuxième édition ... (semaine internationale sur la sensibilisation au plasma) ... conjointe de la Plasma Protein Therapeutics Association ... , l,IPAW vise à : , ... la collecte du plasma-aphérèse , Reconnaître la ...
Breaking Biology Technology:Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 2Global Science & Technology, Inc. Awarded GSA OASIS Small Business Contract 3Blood-cleansing biospleen device developed for sepsis therapy 2Blood-cleansing biospleen device developed for sepsis therapy 3Blood-cleansing biospleen device developed for sepsis therapy 4iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 2iVinci Health Raises $5M to Fuel National Expansion, Announces Launch of Personal Finance Portal for Healthcare 3L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3
... N.J., May 30, 2012  Today, leading events organizer ... to showcase the latest developments and opportunities across a ... by the same team as InformexUSA, North America,s leading ... chemistry, and managed in conjunction with the UBM team ...
... California Institute for Nursing & Health Care (CINHC) released ... pilot New Graduate Nurse Transition to Practice Programs (RN ... San Francisco, found that the programs are making a ... graduates and increasing their employment opportunities in hospitals and ...
... 2012 Sequenom, Inc. (NASDAQ: SQNM ), a ... the Company,s participation at the Jefferies 2012 Global Healthcare Conference ... 4-7, 2012. Harry F. Hixson, Jr., Ph.D., ... beginning at 11:00 a.m. ET, to provide an overview of ...
Cached Biology Technology:Informex Returns To India In 2012 2Informex Returns To India In 2012 3Study Shows Transition to Practice Programs Get Nurses Employed 2
(Date:9/15/2014)... from digestion to disease resistance. Despite the fact that ... the planet, more is known about belly-button bacteria than ... colleagues working on Panama,s Barro Colorado Island discovered that ... to more than 400 different kinds of bacteria. The ... 7,000 different kinds. , Bacteria in tropical forests may ...
(Date:9/15/2014)... 2014) The so-called central dogma of molecular ... provided a simplified explanation for how genetic information ... , In reality, of course, the process is ... nearly 60 years ago by Nobel Laureate Francis ... one, there are multiple types of RNA, three ...
(Date:9/15/2014)... study indicates that lowland tapir populations may continue to ... Researchers from the Office National de la Chasse ... San Diego Zoo Global reviewed data retrieved from camera ... four years and compared this data to current harvest ... on hunting tapirs in French Guiana," said Matthias Tobler, ...
Breaking Biology News(10 mins):Smithsonian scientists discover tropical tree microbiome in Panama 2Scientists discover RNA modifications in some unexpected places 2
... Ireland Cancer Center of University Hospitals Case Medical Center ... breast cancers express the MUC-1 target. This first-of-its-kind finding, ... has paved the way for an upcoming vaccine trial ... that could potentially prevent recurrence of this aggressive type ...
... from the effects of acid rain, as wet weather counteracts ... The research, by Professor Steve Ormerod and Dr Isabelle Durance ... year period around Llyn Brianne in mid-Wales. Their findings are ... of Applied Ecology . Carried out in 14 streams, ...
... PULLAUP, WA This Christmas season, think twice about ... Christmas tree. The good, old-fashioned methodkeeping your tree in ... to keep your tree green and healthy. Researchers have ... Christmas trees; in fact, in several cases the chemical ...
Cached Biology News:Ireland Cancer Center researcher finds most triple-negative breast cancers express muc-1 target 2Climate-change set-back for acidified rivers 2Flame retardants prove ineffective on fresh-cut Christmas trees 2
... locus encodes two unrelated proteins both of ... the cell cycle in a p53-dependent manner. ... rapid degradation of mdm2 proteinrequired for mdm2 ... This interaction is mediated by the ...
human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
...
Gel Loading Buffer contains a precipitant to ensure that the samples sink into the wells and a tracking dye to allow the user to follow the progress of electrophoresis....
Biology Products: